Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes Terrence F. Blaschke Division of Clinical Pharmacology, Department of Purpose of review Medicine, Stanford University School of Medicine, It is generally accepted that a high degree of adherence to the dosing regimens of Stanford, California, USA protease inhibitors is essential to avoid virological failure. It is also believed that Correspondence to Terrence F. Blaschke, MD, Division once-daily dosing of protease inhibitors, by improving adherence, will lead to better of Clinical Pharmacology, Stanford University School of Medicine, S-009 Stanford Medical Center, Stanford, outcomes. This review will discuss the patterns of adherence for once-daily and CA 94305-5130, USA twice-daily regimens and illustrate how differences in these patterns might favor Tel: +1 650 725 4632; fax: +1 650 725 8020; e-mail: Blaschke@stanford.edu twice-daily regimens in some settings. Recent findings Current Opinion in HIV and AIDS 2008, 3:603– 607 Using electronic monitoring of more than 1800 patients enrolled in HIV clinical trials, the fraction of doses taken by patients on a once-daily regimen was about 10% higher than that taken by patients on a twice-daily regimen. However, patients on the twice-daily regimen were less likely to have their trough concentrations fall http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes

Blaschke, Terrence F
Current Opinion in HIV and Aids , Volume 3 (6) – Nov 1, 2008
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/variable-adherence-to-prescribed-dosing-regimens-for-protease-Ye0It15TLO

References (27)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e32831271c2
pmid
19373030
Publisher site
See Article on Publisher Site

Abstract

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes Terrence F. Blaschke Division of Clinical Pharmacology, Department of Purpose of review Medicine, Stanford University School of Medicine, It is generally accepted that a high degree of adherence to the dosing regimens of Stanford, California, USA protease inhibitors is essential to avoid virological failure. It is also believed that Correspondence to Terrence F. Blaschke, MD, Division once-daily dosing of protease inhibitors, by improving adherence, will lead to better of Clinical Pharmacology, Stanford University School of Medicine, S-009 Stanford Medical Center, Stanford, outcomes. This review will discuss the patterns of adherence for once-daily and CA 94305-5130, USA twice-daily regimens and illustrate how differences in these patterns might favor Tel: +1 650 725 4632; fax: +1 650 725 8020; e-mail: Blaschke@stanford.edu twice-daily regimens in some settings. Recent findings Current Opinion in HIV and AIDS 2008, 3:603– 607 Using electronic monitoring of more than 1800 patients enrolled in HIV clinical trials, the fraction of doses taken by patients on a once-daily regimen was about 10% higher than that taken by patients on a twice-daily regimen. However, patients on the twice-daily regimen were less likely to have their trough concentrations fall

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Nov 1, 2008

There are no references for this article.